Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Association Between Helicobacter Pylori and Inflammatory Bowel Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03820284
Recruitment Status : Recruiting
First Posted : January 29, 2019
Last Update Posted : January 30, 2019
Sponsor:
Information provided by (Responsible Party):
Bahaa osman taha, Assiut University

Brief Summary:

Introduction:

Helicobacter pylori has been linked to a variety of gastric and extra gastric diseases. Chronic infection with H. pylori causes histologically evident gastritis in all colonized individuals and is the predominant risk factor for gastric and duodenal ulcers as well as gastric adenocarcinoma. However, increasingly robust experimental and epidemiological evidence suggests that H. pylori may at the same time be beneficial to its carriers, as it efficiently prevents allergic disorders and chronic inflammatory conditions .

Inflammatory bowel disease (IBD) is characterized by chronic, nonspecific intestinal inflammation with an unexplained pathology and an alternating relapsing and remitting clinical progression. IBD is divided into two subtypes: ulcerative colitis (UC) and Crohn's disease (CD). Most studies in the IBD field attribute its etiology to the complex interactions among immune dysfunction, genetic susceptibility of the host, and environmental risk factors.

Since the twenty-first century, improving hygienic conditions and socioeconomic status have reduced the H. pylori infection rate and this trend has concurrently been accompanied by an increased IBD incidence in most countries Numerous studies have reported a lower H. pylori infection rate in patients with CD and/or UC than in non-IBD control individuals. although a small number of studies showed no significant association .Recently, emerging epidemiologic studies and animal experiments revealed an inverse correlation between H. pylori infection and IBD onset, suggesting that H. pylori colonization exerts a special protective effect on autoimmune diseases

observation Cross sectional study will be conducted at assuit university hospitals on all patients with inflammatory disease to detect the prevalence of helicobacter pylori among them .Then the examined patients will be divided in to two group receiving the same medication group A : inflammatory bowel disease patient with H.PYLORI group B: inflammatory bowel disease Patient without H.PYLORI longitudinal study will be conducted to both group to study the clinical outcomes in both group .


Condition or disease
Helicobacter Infections

Detailed Description:

PATIENT AND METHOD :

observation Cross sectional study will be conducted at assuit university hospitals on all patients with inflammatory disease to detect the prevalence of helicobacter pylori among them .Then the examined patients will be divided in to two group receiving the same medication group A : inflammatory bowel disease patient with H.PYLORI group B: inflammatory bowel disease Patient without H.PYLORI longitudinal study will be conducted to both group to study the clinical outcomes in both group .

  1. Thorough medical history and full clinical examination will be taken from all patient including

    -Personal history focus on special habit especially smoking

    -documented previous history for H.pylori eradication

    • Onset and duration of inflammatory bowel disease
    • current medication
    • presence of any extra intestinal manifestation of Inflammatory bowel disease
    • presence of any complications from Inflammatory bowel disease
  2. Investigation :

    -All patients with inflammatory bowel disease will be tested for presence or absence of H.PYLORI by histological examination of endoscopically biopsied gastric mucosa

    -his to logical examination of colonic mucosal every 3 months

    -complete blood count

    -serum albumin

    -c reactive protein, erythrocyte sedimentation rate (ESR).

    -fecal calprotectin if possible

    • assess the severity of among both group (A,B) every 3 month for 2years. ulcerative by Mayo Score/Ulcerative Colitis Disease Activity Index and Crohn's disease by Montreal classifications for Crohn's Disease .

    Mayo Score/Ulcerative Colitis Disease Activity Stool frequency 0 = Normal 1 = 1-2 stools/day more than normal 2 = 3-4 stools/day more than normal 3 = 4 stools/day more than normal Rectal bleeding 0 = None 1 = Visible blood with stool less than half the time 2 = Visible blood with stool half of the time or more 3 = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1 = Mild disease (erythema, decreased vascular pattern, mild friability) 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 3 = Severe disease (spontaneous bleeding, ulceration) Physician rating of disease activity 0 = Normal 1 = Mild 2 = Moderate 3 = Severe

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Association Between Helicobacter Pylori and Inflammatory Bowel Disease
Estimated Study Start Date : February 1, 2019
Estimated Primary Completion Date : February 1, 2019
Estimated Study Completion Date : February 1, 2021

Group/Cohort
Group A
Group A inflammatory bowel disease with helicobacter pylori infection
Group B
Inflammatory bowel disease without helicobacter pylori infection



Primary Outcome Measures :
  1. prevalance of H.pylori among patients with inflammatory bowel disease [ Time Frame: One years ]
    Number of patient with inflammatory bowel disease with H.pylori infection

  2. Mayo score activity index among ulcerative colitis patients with H.pylori and without H.pylori [ Time Frame: Two years ]
    Stool frequency 0 = Normal 1 = 1-2 stools/day more than normal 2 = 3-4 stools/day more than normal 3 = 4 stools/day more than normal Rectal bleeding 0 = None 1 = Visible blood with stool less than half the time 2 = Visible blood with stool half of the time or more 3 = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1 = Mild disease (erythema, decreased vascular pattern, mild friability) 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 3 = Severe disease (spontaneous bleeding, ulceration) Physician rating of disease activity 0 = Normal 1 = Mild 2 = Moderate 3 = Severe

  3. Mucosal healing among inflammatory bowel disease with H.pylori and without H.pylori [ Time Frame: 1years ]
    Histological examination of the biopsied colonic mucosal every 3 months in both groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Inflammatory bowel disease patients with or without H.pylori infection
Criteria

Inclusion Criteria:

  • all inflammatory bowel disease at assiut university will be included and examined in cross sectional study for detection of presence of H.pylori in one year 2019-2020 .then the examined patients will be divided in two group A ,B according to presence or absence of H pylori . Both group will be studied in cohort study for two years

Exclusion Criteria:

  • -patients with history of administration of proton pump inhibitor or antibiotics with in eight weeks .
  • patients with history of recent upper gastrointestinal bleeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03820284


Contacts
Layout table for location contacts
Contact: Bahaa Os Taha, Master degree 01015599135 bahaa_osman99@aun.edu.eg
Contact: Alaa El Abdel monem, Doctorate of internal medicine

Locations
Layout table for location information
Egypt
Bahaa osman taha Recruiting
Assiut, Egypt
Contact: Bahaa Osman Taha    01015599135      
Contact: Alaa Eldein Ahmed    01015599135      
Sponsors and Collaborators
Assiut University
Investigators
Layout table for investigator information
Principal Investigator: Bahaa Os Taha, Master of internal medicine Assiut University
Study Director: Zain elabdeen Ah Sayed, Doctorate of internal medicine Assiut
Study Chair: Alaa El Abdelmonem, Doctorate of internal medicine Assiut University
Layout table for additonal information
Responsible Party: Bahaa osman taha, Principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03820284    
Other Study ID Numbers: L23457
First Posted: January 29, 2019    Key Record Dates
Last Update Posted: January 30, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Helicobacter Infections
Inflammatory Bowel Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Gram-Negative Bacterial Infections
Bacterial Infections